$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000162828019006463 Filed on May 09, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$64.83M	$57.66M
YoY Change	12.44%	108.92%
Cost Of Revenue	$1.240M	$1.174M
YoY Change	5.62%	81.73%
Gross Profit	$63.59M	$56.49M
YoY Change	12.58%	109.57%
Gross Profit Margin	98.09%	97.96%
Selling, General & Admin	$24.39M	$18.44M
YoY Change	32.26%	22.63%
% of Gross Profit	38.35%	32.65%
Research & Development	$20.24M	$17.05M
YoY Change	18.73%	137.6%
% of Gross Profit	31.84%	30.19%
Depreciation & Amortization	$96.00K	$48.00K
YoY Change	100.0%	269.23%
% of Gross Profit	0.15%	0.08%
Operating Expenses	$44.63M	$35.49M
YoY Change	25.76%	59.77%
Operating Profit	$18.96M	$21.00M
YoY Change	-9.71%	342.93%
Interest Expense	$1.100M	$290.0K
YoY Change	279.31%	-207.41%
% of Operating Profit	5.8%	1.38%
Other Income/Expense, Net	$1.097M
YoY Change
Pretax Income	$20.05M	$21.29M
YoY Change	-5.81%	371.52%
Income Tax	$1.800M	$3.830M
% Of Pretax Income	8.98%	17.99%
Net Earnings	$18.27M	$17.46M
YoY Change	4.67%	297.88%
Net Earnings / Revenue	28.19%	30.28%
Basic Earnings Per Share	$0.16	$0.15
Diluted Earnings Per Share	$0.15	$0.14
COMMON SHARES
Basic Shares Outstanding	114.8M shares	114.9M shares
Diluted Shares Outstanding	123.9M shares	127.7M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$186.9M	$125.4M
YoY Change	49.04%	137.5%
Cash & Equivalents	$49.65M	$33.12M
Short-Term Investments	$137.3M	$92.20M
Other Short-Term Assets	$5.700M	$3.300M
YoY Change	72.73%	83.33%
Inventory	$5.000M	$4.900M
Prepaid Expenses
Receivables	$19.22M	$17.30M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$216.9M	$150.8M
YoY Change	43.81%	126.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$925.0K	$600.0K
YoY Change	54.17%	100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$28.80M	$15.00M
YoY Change	92.0%	233.33%
Other Assets	$75.00K	$76.60M
YoY Change	-99.9%	1864.1%
Total Long-Term Assets	$103.3M	$92.20M
YoY Change	12.09%	967.25%
TOTAL ASSETS
Total Short-Term Assets	$216.9M	$150.8M
Total Long-Term Assets	$103.3M	$92.20M
Total Assets	$320.2M	$243.0M
YoY Change	31.77%	222.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.330M	$7.900M
YoY Change	18.1%	85.75%
Accrued Expenses	$18.83M	$19.20M
YoY Change	-1.93%	93.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.22M	$27.70M
YoY Change	23.53%	7.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$200.0K
YoY Change
Total Long-Term Liabilities	$200.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.22M	$27.70M
Total Long-Term Liabilities	$200.0K	$0.00
Total Liabilities	$34.46M	$27.70M
YoY Change	24.39%	7.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$99.46M
YoY Change
Common Stock	$427.4M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$285.8M	$215.2M
YoY Change
Total Liabilities & Shareholders Equity	$320.2M	$243.0M
YoY Change	31.77%	222.54%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	$18.27M	$17.46M
YoY Change	4.67%	297.88%
Depreciation, Depletion And Amortization	$96.00K	$48.00K
YoY Change	100.0%	269.23%
Cash From Operating Activities	$23.68M	$34.43M
YoY Change	-31.22%	258.65%
INVESTING ACTIVITIES
Capital Expenditures	$257.0K	$77.00K
YoY Change	233.77%	-30.0%
Acquisitions
YoY Change
Other Investing Activities	-$100.0K	-$34.20M
YoY Change	-99.71%	77.2%
Cash From Investing Activities	-$367.0K	-$34.29M
YoY Change	-98.93%	76.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$13.56M	$0.00
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	-$15.29M	$1.922M
YoY Change	-895.47%	-151.95%
NET CHANGE
Cash From Operating Activities	$23.68M	$34.43M
Cash From Investing Activities	-$367.0K	-$34.29M
Cash From Financing Activities	-$15.29M	$1.922M
Net Change In Cash	$8.025M	$2.059M
YoY Change	289.75%	-115.25%
FREE CASH FLOW
Cash From Operating Activities	$23.68M	$34.43M
Capital Expenditures	$257.0K	$77.00K
Free Cash Flow	$23.42M	$34.35M
YoY Change	-31.81%	261.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	cort	Accretion Of Interest Income Expense AccretionOfInterestIncomeExpense	-198000	USD
CY2019Q1	cort	Accretion Of Interest Income Expense AccretionOfInterestIncomeExpense	-634000	USD
CY2018Q4	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	3521000	USD
CY2019Q1	cort	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	4537000	USD
CY2018Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11132000	USD
CY2019Q1	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	10829000	USD
CY2018Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	314000	USD
CY2019Q1	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	531000	USD
CY2018Q4	cort	Accrued Manufacturing Costs AccruedManufacturingCosts	2032000	USD
CY2019Q1	cort	Accrued Manufacturing Costs AccruedManufacturingCosts	70000	USD
CY2018Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	1239000	USD
CY2019Q1	cort	Increase Decrease In Accrued Clinical Expenses IncreaseDecreaseInAccruedClinicalExpenses	1016000	USD
CY2019Q1	cort	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-357000	USD
CY2018Q1	cort	Interest And Other Income Expense InterestAndOtherIncomeExpense	294000	USD
CY2019Q1	cort	Interest And Other Income Expense InterestAndOtherIncomeExpense	1097000	USD
CY2018Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	16242000	USD
CY2019Q1	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	15360000	USD
CY2018Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	6423000	USD
CY2019Q1	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	6369000	USD
CY2018Q4	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	4195000	USD
CY2019Q1	cort	Inventory Raw Materials Current And Noncurrent InventoryRawMaterialsCurrentAndNoncurrent	2055000	USD
CY2018Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	5624000	USD
CY2019Q1	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	6936000	USD
CY2019Q1	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P2Y
CY2019Q1	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P6M
CY2019Q1	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	1878000	USD
CY2018	cort	Number Of Compounds NumberOfCompounds	500	compound
CY2019Q1	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	3	series
CY2019Q1	cort	Number Of Stock Option Plans NumberOfStockOptionPlans	2	stock_option_plan
CY2019Q1	cort	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	413000	USD
CY2018Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	0	USD
CY2019Q1	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	931000	USD
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001088856
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	114858708	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	CORCEPT THERAPEUTICS INC
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q1	dei	Trading Symbol TradingSymbol	CORT
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8266000	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	9330000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17588000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19218000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1542000	USD
CY2019Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2462000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1174000	USD
CY2018Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	239000	USD
CY2019Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	239000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1240000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	36664000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23786000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18830000	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	261000	USD
CY2019Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	699000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	240000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	493000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-70000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	94000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	417228000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	427317000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	5100000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4954000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6724000	USD
CY2018Q4	us-gaap	Assets Assets	311694000	USD
CY2019Q1	us-gaap	Assets Assets	320212000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	236820000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	216864000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41625000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49650000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31062000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33121000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41625000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49650000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2059000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8025000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	117000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	118000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	17307000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	18438000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	45873000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	62659000	USD
CY2019Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	61681000	USD
CY2018Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3169000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	926000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	48000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	96000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.16
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	635000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1999000	USD
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	12851000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9051000	shares
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	25000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7879000	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3296000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	28000	USD
CY2018Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-54000	USD
CY2019Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	0	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	21289000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	20053000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3800000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3830000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1779000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800000	USD
CY2019Q1	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-2800000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-12876000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-759000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	953000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1961000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1630000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-3200000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-900000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-590000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-910000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2383000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-4956000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	23000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4732000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	5000000	USD
CY2018Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	11510000	USD
CY2019Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	10360000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1563000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	391000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1172000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	35812000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	34457000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	311694000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	320212000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	35573000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	34218000	USD
CY2019Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2019Q1	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	165135000	USD
CY2019Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	137255000	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	USD
CY2019Q1	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	28842000	USD
CY2018Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-77000	USD
CY2019Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	164000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1922000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15289000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34293000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-367000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	34430000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	23681000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	17459000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	18274000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	20995000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	18956000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1521000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1521000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	379000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1465000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2019Q1	us-gaap	Option Indexed To Issuers Equity Settlement Alternatives Shares At Fair Value OptionIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue	800000	shares
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	386000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	450000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-152000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	164000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	48000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-52000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13555000	USD
CY2018Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4169000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	50866000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	70935000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	77000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	257000	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7740000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5741000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1922000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	2435000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	16650000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	70825000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	17459000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	18274000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	655000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	925000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17050000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20244000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-117736000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99462000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57659000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64829000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1878000	USD
CY2018Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	18440000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24389000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4954000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6696000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23100000	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24400000	shares
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	4954000	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	6724000	USD
CY2018Q1	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	600000	USD
CY2019Q1	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	900000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1922000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3366000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	190968000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	215226000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	275882000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	285755000	USD
CY2018Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	23657000	USD
CY2019Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	42312000	USD
CY2019Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	13555000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127733000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123895000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114882000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114844000	shares

Files In Submission

Name	View Source	Status
0001628280-19-006463-index-headers.html	Edgar Link	pending
0001628280-19-006463-index.html	Edgar Link	pending
0001628280-19-006463.txt	Edgar Link	pending
0001628280-19-006463-xbrl.zip	Edgar Link	pending
cort-20190331.xml	Edgar Link	completed
cort-20190331.xsd	Edgar Link	pending
cort-20190331_cal.xml	Edgar Link	unprocessable
cort-20190331_def.xml	Edgar Link	unprocessable
cort-20190331_lab.xml	Edgar Link	unprocessable
cort-20190331_pre.xml	Edgar Link	unprocessable
cort3311910-qdoc.htm	Edgar Link	pending
cort33119ex101.htm	Edgar Link	pending
cort33119ex102.htm	Edgar Link	pending
cort33119ex311.htm	Edgar Link	pending
cort33119ex312.htm	Edgar Link	pending
cort33119ex321.htm	Edgar Link	pending
cort33119ex322.htm	Edgar Link	pending
cortlogo.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2019 Q1 Form 10-Q Financial Statement

#000162828019006463 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2019 Q1 Form 10-Q Financial Statement

#000162828019006463 Filed on May 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort